zorevunersen (STK-001)
STK-001-DS-501
Phase 2 small_molecule active
Quick answer
zorevunersen (STK-001) for Dravet Syndrome is a Phase 2 program (small_molecule) at Stoke Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Stoke Therapeutics
- Indication
- Dravet Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active